Evidence map›Paper›PMID 42377754›Full record

ReviewMolecular biology reports2026

EphA2 as an oncogenic driver: roles and mechanisms of action in cancer.

Hanbing Song, Ning Qin, Xiaohe Feng, Chen Han, Yun Liu, Yunsha Jia, Peiyuan Lu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanbing SongSchool of Medicine, Shandong Xiehe University, Jinan, China.
Ning QinSchool of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, China.ORCID http://orcid.org/0009-0001-5341-0623
Xiaohe FengSchool of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, China.
Chen HanSchool of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, China.ORCID http://orcid.org/0000-0001-5151-2223
Yun LiuSchool of Medicine, Shandong Xiehe University, Jinan, China.
Yunsha JiaSchool of Medicine, Shandong Xiehe University, Jinan, China.
Peiyuan LuSchool of Medicine, Shandong Xiehe University, Jinan, China. lupeiyuan@sdxiehe.edu.cn.ORCID http://orcid.org/0000-0001-8163-415X

Funding

National Natural Science Foundation of China 82104455Shandong Xiehe University SDXHQD2025039
6 · The paper itself

Abstract

Receptor tyrosine kinases are key regulators of various fundamental cellular processes, and dysregulation of their activities may lead to many human diseases including cancer. EphA2 is a member of the Eph subfamily of receptor tyrosine kinases that play an important role in regulating tissue patterning, homeostasis, and regeneration. Accumulating evidence indicates that EphA2 is a critical regulator of cancer development and progression and can function as both a tumor suppressor and an oncogenic driver. When acting as an oncogenic driver, EphA2 can promote tumor initiation, growth, invasion, metastasis, stemness, and angiogenesis by activating or enhancing the oncogenic signaling pathways. High expression of EphA2 in a wide range of human tumor tissues is closely associated with poor prognosis, thus it is a very promising target for cancer treatment. A number of studies on EphA2-targeted cancer treatment are currently at the clinical trial stage. In this review, we discuss the oncogenic roles and mechanisms of action of EphA2 in cancer development and progression, which could provide novel insights into EphA2-targeted cancer treatment.

Indexed as

NeoplasmsReceptor, EphA2AnimalsCarcinogenesisDisease ProgressionGene Expression Regulation, NeoplasticHumansOncogenesSignal TransductionEPHA2 protein, humanReceptor, EphA2Cancer developmentCancer progressionEphA2Signaling pathwaysTyrosine phosphorylation

Identifiers

PMID42377754

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.